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INTRODUCTION
Natural cell-mediated cytotoxicity (NCMC) is 
a major component of innate cellular immunity 
against cancer and infection. NCMC is mediated 
primarily by leucocytes which perform natural 
killing (NK) and natural cytotoxicity (NC) without 
the requirement for prior sensitization and there is 
no immunological memory associated with this type 
of responses. This mechanism is characteristically 
and functionally different from the cell-mediated 
cytotoxicity of cytotoxic T lymphocytes. Cells 
mediating NK and NC are two distinct and 
probably related NCMC effector mechanisms 
which are distinguishable from each other by the 
time differences required to mediate their killing, as 
well as  the kinetics of their appearance and decline 
in mice[1-3]. 
Natural killer (NK) cells belong to an important 
lymphocyte population that eliminates transformed 
cells and invading viral pathogens without any prior 
sensitization. These cells possess not only natural 
killing activity against non-self and altered-self cells 
but also exhibit cytokine production and antibody-
dependent cell-mediated cytotoxicity (ADCC)[4]. 
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Objectives: To identify the expression of NC-2 on 
an interleukin-3 dependent mast cell line (MCL) and 
investigate the activity of this receptor against tumor 
cells
Design: Laboratory study
Setting: Cellular and Molecular Center, Shahrekord, Iran 
Subjects and Methods: The MCL cells were stained with 
D9 monoclonal antibody (anti-NC-2) and analysed by ﬂow
cytometry. This was conﬁrmed by immunoperoxidase
staining. The cytotoxicity assay was performed to show 
the cytotoxic activity of MCL cells against 51Cr-labelled 
WEHI-164 tumor cells.
Intervention:  The expression of NC-2 on MCL cells, and 
the anti-tumor activity of this receptor were investigated.
Main Outcome Measure(s): Flow cytometric analysis 
and in vitro experiments were performed for showing the 
activity of NC-2 against cancer. 
Results: NC-2 receptor was expressed on more than 
95% of MCL cells. Pretreatment with D9 monoclonal 
antibody resulted in about 63% reduction in natural 
cytotoxicity of MCL cells against WEHI-164 tumor 
target cells. 
Conclusions: NC-2 is also one of the receptors expressed 
on MCL and utilized for WEHI-164 tumor cell killing.
It has been shown that NK cells might not serve 
merely as cytotoxic lymphocytes combating viral 
pathogens and malignant tumors, but must also be 
considered as important immunoregulatory cells 
with a signiﬁcant inﬂuence on adaptive immunity[5]. 
The effector’s functions of NK cells are regulated by 
integrated signals across the array of stimulatory 
and inhibitory receptors engaged upon interaction 
with target cell surface ligands[6]. Intensive research 
during the 1990s has deﬁned a large number of
activating and inhibitory receptors[7-9]. NK cells 
are heterogeneous in their receptor repertoire, 
in the sense that different cells express different 
combinations of activating and inhibitory receptors. 
In addition, a functional heterogeneity is emerging, 
at least in the human. The majority of blood NK cells 
express moderate levels of CD56 in combination with 
various molecules of killer cell immunoglobulin 
receptor (KIR) family[10]. In addition, there is a small 
subpopulation of blood NK cells that express high 
levels of CD56 in combination with the inhibitory 
receptor NKG2A, and no receptors of the KIR family. 
This subset has low perforin levels and seems to be 
specialized for high cytokine secretion rather than 
KUWAIT MEDICAL JOURNAL 113June 2009
direct killing. The latter subset may be the only NK 
cells present in the lymph nodes, an organ that was 
initially thought to be completely devoid of NK 
cells[11]. Human NK cells can be divided into two 
functional subsets based on their surface expression 
of CD56; CD56 (bright) immunoregulatory cells 
and CD56 (dim) cytotoxic cells. The importance 
of early hematopoietic growth factors, such as c-
kit ligand and ﬂt-3 ligand, and their synergy with
IL-15 in the development of human NK cells in the 
bone marrow has permitted the investigation of 
novel cytokine combinations for optimizing in vivo 
expansion of NK cell in the clinic. The importance 
of lymph nodes as a site for NK cell development 
has recently been elucidated[12]. 
The major differences between NK and NC 
are the receptors and mechanisms involved in 
cytotoxicity[13-15]. The initial step in the mechanism 
of cytotoxicity of NK and NC is the recognition 
and binding of effector cells to tumor cells via 
receptor-ligand interactions. A number of these 
receptors have been identiﬁed on human and
rodent leucocytes mediating NK cytotoxicity. To 
date, however, only two such receptors, NC-1.1 and 
NC-2 were recognized[16,17]. NC-1.1 was identiﬁed
by a mouse anti-mouse monoclonal antibody 
(mAb) 1C4 (anti-NC-1.1). It is a monomeric 
phosphoprotein of 45,000 MW expressed on the 
surface of predominantly large and granular 
leucocytes of different hemopoietic cell lineages[16]. 
Flow cytometric analysis showed that NC-1.1 is 
expressed on less than 5% of fresh CBA mouse spleen 
cells and 20-50% of CBA- interleukin-3 cells. In vitro 
treatment of spleen cells from a number of inbred 
mouse strains with anti-NC-1.1 (1C4), markedly 
decreased NC activity of spleen cells against 51Cr- 
labeled WEHI-164 targets[16]. Administration of a 
single dose of 1C4 in a number of mouse strains 
depletes NC activity from the spleens of mice for at 
least one week, with the maximal effect occurring 
24 hours after treatment[18]. NC-2 was identiﬁed
by a rat anti-mouse monoclonal antibody D9 (anti-
NC-2). It is a 50,000 MW molecule expressed on the 
surface of mainly large and granular leucocytes in 
mice. This receptor is expressed on < 6% of splenic 
leukocytes of different inbred mouse strains. 
Pretreatment of (CBA × C57BL/6) F1 mouse spleen 
cells with different doses of mAb D9 in vitro blocked 
NC against WEHI-164, whereas NK activity against 
YAC-1 was not affected[17].  By culturing CBA 
mouse spleen cells in interleukin-3 conditioned 
media, a stable cell line called mast cell line (MCL) 
was generated[19]. It has been shown that this cell 
line has high natural cytotoxicity against WEHI-164 
tumor target cells and was used as a NC like cell line 
to characterize natural cytotoxic cells. These cells 
expressed NC-1.1 receptor but not characteristic cell 
surface markers of T, B lymphocytes, macrophages, 
or NK cell. Pretreatment of MCL cells with anti-
NC1.1 antibody blocked the NC activity of these 
cells by approximately 70%[19,20] .
This article reports the expression of NC-2 on 
MCL cells, and the investigation of the activity of 
this receptor.
MATERIAL AND METHODS
Tissue culture medium (TCM)
The study was conducted in the cellular and 
molecular research center at Sharekord University 
of Medical Sciences, Iran. Approval of the ethical 
committee was obtained.   Dulbecco’s modiﬁcation
of eagles medium (CSL, Melbourne, Victoria, 
Australia) was supplemented with 20 mm HEPES, 
2 mM L- glutamine, 50 µM 2-mercaptoethanol, 
0.15% sodium bicarbonate, 50 µg/ml gentamicin 
and 10% fetal calf serum (FCS). The supplemented 
TCM was then further conditioned either with IL-3 
for growth of MCL or with IL-2 for C57BL/6 IL-
2 dependent cell lines. Cell lines and monoclonal 
antibodies.
NK-like MCL  and NK-like C57BL/6-interleukin-
2 (IL-2) dependent cell lines were generated[19,20]. 
WEHI-164 (a BALB/c ﬁbrosarcoma) was provided
by Walter and Elisa Hall Institute, Melbourne, 
Australia. The mAbs used were anti-NC-2 mAb D9 
(rat IgG2a) and anti–CD32/CD16 (rat IgG2b; clone 
2.4G2, anti-Fc gamma receptor RII/RIII). 
Flow cytometric analysis
MCL (NC like) and C57BL/6-IL2 (NK like) cells 
were harvested and washed in PBS containing 1% FCS 
at 5x105cells/ml. One hundred micro liter of each cell 
suspension were aliquoted into each staining tubes. 
After blocking Fc receptors with 2.4G2 mAb, the 
cells were incubated either with 100 µl biotinylated 
D9 mAb and rat IgG2a isotype control mAb for 30 
min on ice, followed by a further incubation with 
streptavidin–ﬂuoroscein isothiocyanate (FITC)
complex  (Amersham, Buckinghamshire, UK). After 
two washes, the cells were re-suspended in 250µl 
PBS and analyzed in the FACScan automated ﬂow
cytometer using the CELL QUEST software (Becton 
Dickinson Immunocytometry Systems, San Jose, 
CA). Five thousand cells were acquired for analysis 
in ﬂow cytometer[20]. 
Immunoperoxidase Staining techniques
Fresh MCL cells were cytocentrifuged onto 
gelatin coated slides. The specimens were air 
dried and ﬁxed in acetone for 10 minutes. The
ﬁxed cells were incubated with 100 µl of pretitred
anti-Fc gamma receptor (2.4G2) for 30 minutes. 
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The slides were washed with PBS pH 9.6 and 
incubated with 100 µl of pretitered mAb D9 in a 
humid box at room temperature for 30 minutes. 
Endogenous peroxidase activity was quenched 
in a 2% w/v hydrogen peroxidase/methanol 
bath for 10 minutes. The specimen were then 
incubated with 100 µl strepavidin-conjugated 
Horse-Radish-Peroxidase conjugate (Amersham, 
Buckinghamshire, UK), followed by reaction with 
3,3-diaminobenzidine tetrahydrochloride (DAB) 
(Sigma, St Louis, MO,USA) for not more than 10 
minutes. The cells were washed with tap water 
and counter stained with Carazzi,s hematoxylin 
(Histo-Lab Fronine, NSW, Australia) with 
replacement of slides into Carazzi,s hematoxylin 
for two minutes, followed by rinsing in tap water. 
The slides were then dipped in 1% acid alcohol 
for ﬁve seconds and then transferred into Scott's
tap water for two minutes. The slides were then 
dehydrated through three lots of 70% and two 
of 100% ethanol and then mounted with natural 
mounting medium (Ajax Chemicals, Australia) 
for microscopic analysis.
Cytotoxicity assay
NC activity was assayed by in vitro lysis of 51Cr-
labelled WEHI-164, as previously described[19]. 
The experiment was conducted in quadruplicate 
in 200 µl TCM in 96-well micro-titer trays. Brieﬂy,
MCL cells were incubated with 51Cr-labelled 
targets at effector / target (E : T) ratios in the 
range of 100:1-12.5:1. The cells were incubated at 
37 oC / 5% CO2 for 18 hr. Supernatants (100 µl) 
from each well were harvested and the level of 
radioactivity was measured in a COBRA gamma-
counter (Packard Instrument CO., Downer’s 
Grove, Illinois). The results were ﬁrst calculated
as percentage speciﬁc lysis:
Percent speciﬁc lysis = CPM (Sample) - CPM (Background) ×     100
        CPM (Total Release) - CPM (Background)
Background count per million (CPM) was obtained 
from wells containing target cells alone and total 
release was determined by counting 51Cr-labelled 
target cells. Lytic units (LU) were calculated from the 
linear portion of a graph of percentage speciﬁc lysis
versus E:T ratios. One LU is herein deﬁned as the
number of effector cells which mediate 20% speciﬁc
lysis of the target cells. Results are expressed either 
as LU per 108 MCL or percentage reductions in LU 
according to the following formula:  
Percent reduction in LU   =   LU (control)- LU (D9 treated)  × 100
                       LU (control)
For antibody blocking studies, the MCL cells 
were pretreated with mAb D9 or isotype matched 
mAb, washed and resuspended to the original 
volume prior to use in the cytotoxicity assay[21].
RESULTS
To show the expression of NC-2 on MCL 
and NK-like C57BL/6-IL2 cells, ﬂow cytometric
analysis was performed. Results showed that 
mAb D9 (anti NC-2 receptor) bound to more than 
Fig. 1: Flow cytometric analysis showing expression of NC-2 receptor on (A) MCL (NC like) but not on (B) C57BL/6-IL2 (NK like) 
cell line. The cells were ﬁrst incubated with mAb 2.4G2 (anti-CD32/CD16) and then with mAb D9 (anti-NC-2). (...) ﬂuorescence
histograms of cells stained with rat IgG2a isotype mAb and (   ) cells stained with mAb D9.
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95% of NC-like MCL cells, but not to the NK- like 
C57BL/6-IL2 NK-like cells (Fig. 1). To conﬁrm
the ﬂowcytomery ﬁnding, immunoperoxidase
staining technique was carried out on fresh MCL 
cells; results approved the ﬂow cytometric ﬁnding
(Fig. 2). 
Natural cytotoxic activity of MCL cells was 
assayed by in vitro lysis of 51Cr-labelled WEHI-164 
cells (NC tumor target). Results demonstrated the 
maximal lysis of WEHI-164 target at 18 hours in 
the cytotoxicity assay. The lytic units of MCL cells 
were reduced by approximately 63% following 
pretreatment of cells with mAb D9 compared to the 
control cells treated with IgG2a isotype matched 
mAb (Fig. 3).
DISCUSSION
Our ﬂow cytometry results showed that NC-2
receptor is expressesd on about 95% of MCL cells, 
this was conﬁrmed by immunoperoxidase staining
technique. Furthemore, in a 51Cr-release assay, anti-
NC-2 antibody (D9) blocked 63% of NC activity 
in vitro. Previous study showed that NC-2 is 
expressed on about 6% of (C57BL/6 × CBA) F1 and 
BALB/c and about 4% of C57BL/6 and CBA mice 
spleen cells. Anti-NC2 antibody blocked 60% of NC 
activity of splenic leukocytes in a cytotoxicity assay 
[17]. It has been previously reported that NC-1.1 is 
a molecule expressed on spleen cells of different 
mouse strains[14,16] and as reported in our previous 
publication the NC-1.1 receptor is also presents on 
MCL cell line[19]. Further studies showed additional 
effects of anti-NC-2 (D9) and anti-NC-1.1 (1C4) on 
cytotoxicity of mice spleen cells and suggested that 
NC-1.1 and NC-2 are two different receptors on 
mouse spleen cells. Western blot analysis of afﬁnity
puriﬁed NC-1.1 and NC-2 indicated that the 
receptor identiﬁed by mAb D9 (anti-NC-2) is not
the previously described NC-1.1[17]. Co-expression 
of NC-1.1 and NC-2 on granular splenic leukocytes 
of (C57BL/6  X CBA) F1 mice was examined by dual 
color ﬂow cytometry. Results showed that all NC-2+ 
granular leukocytes co-expressed NC-1.1 whereas 
the converse was not true[17]. Our present ﬁnding
suggests that, similar to previous reports on 
different inbred mouse strains, NC-1.1 and NC-2 
are two distinct receptors which are expressed on 
MCL cells. Furthermore, it is possible that in MCL 
cells population there is a group of cells which may 
have both the receptors, which in turn probably 
abrogates the cytotoxicity of each individual 
receptor[22]. 
Recent studies on NK cells have identiﬁed
multiple receptors which recognize ligands on the 
surface of target cells. These receptors belong to 
two multi-gene families, NKR-P1 and Ly-46, which 
display either activation or inhibition effects on 
natural killing[13]. Upon ligation to its speciﬁc ligand
the receptor either transduces a positive signal to 
the effectors to kill the target cell or a negative signal 
to turn off the killing thus providing a delicate 
regulatory mechanism to control cytotoxicity[14].       
Phosphorylation studies of NC-1.1 showed 
that key intracellular signaling pathway involving 
protein kinase C (PKC) and protein kinase G (PKG) 
interact to effect a coordinated control of NC. The 
fact that increase in phosphorylation up-regulates 
NC argues for NC-1.1 to be an activated receptor[14]. 
Biochemical studies to determine whether NC-2 is 
Fig. 2: Immunoperoxidase staining of MCL cells: Cytocentrifuged 
MCL cells were stained with either IgG2a Isotype matched mAb 
(A) or mAb D9 (B).
Fig. 3: Effect of in vitro treatment of mAb D9 on the NC activity of 
MCL cells: Cytotoxic activity of MCL cells was assayed by in vitro 
lysis of 51Cr-labelled WEHI-164 cells. The lytic units of MCL cells 
were reduced by approximately 63% following pretreatment of 
cells with mAb D9 compared to the control cells treated with 






also a signaling receptor are in progress, and data 
to date suggest that NC-2, like NC-1.1, may also 
be an activation receptor. In order to achieve a 
balanced control in the regulation of NC, it is likely 
that inhibitory receptors also exist on leukocytes 
mediating natural cytotoxicity.   
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